Premium
Administration of iodinated contrast: What is the risk in cancer patients?
Author(s) -
González Cervantes Jose Javier,
Mascarós Martínez Juan Manuel,
Arana Estanislao
Publication year - 2021
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.13351
Subject(s) - medicine , logistic regression , renal function , observational study , odds ratio , iodinated contrast , kidney cancer , univariate analysis , prospective cohort study , statistical significance , cancer , urology , multivariate analysis , radiology , computed tomography
Abstract Objective Despite the association between intravenous contrast and kidney injury, few studies exist in oncology. Our objective was to estimate kidney outcomes following iodinated contrast‐enhanced computed tomography (CECT) in cancer patients, and to evaluate whether self‐assessment questionnaires can identify kidney injury risk factors. Methods This prospective observational study included 289 patients who underwent a CECT scan between March and May 2017 in a hospital setting. All patients completed the modified European Society of Urogenital Radiology (ESUR) questionnaire and had an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m 2 on the day of the examination. Outcomes were followed for 4 months. Univariate and logistic regression analyses were carried out. Results In the logistic regression analysis, the only variables statistically associated with deterioration in the eGFR were age, (odds ratio (OR) = 1.091, p = 0.003), female sex, (OR 0.22, p = 0.020) and arterial hypertension (AH), (OR = 3.57, p = 0.019). Regarding exitus, only the group with a worse eGFR was close to predictive statistical significance (OR = 2.48, p = 0.09). Conclusions The administration of iodinated contrast in cancer patients was not associated with an increase in kidney outcomes. Risk factors in these patients were age, sex and AH.